– USA, MA – Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells for the treatment of cancer, today announced the appointment of David Lubner, a senior finance executive with over 25 years of experience, to its Board of Directors.
“David’s expertise as a life sciences leader with a deep understanding of strategy, finance, capital markets and operations will benefit us greatly moving forward as we continue to build our company and platform and develop therapies for patients,” said CEO, Robert Ang.
About David Lubner
Most recently, Mr. Lubner served as EVP and CFO of Ra Pharma until May 2020 following its acquisition by UCB. Prior to Ra Pharma, he served as SVP and CFO of Tetraphase Pharmaceuticals and as CFO of PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company. He was also CFO at ProScript, where Velcade® (bortezomib), a therapy widely used for the treatment of the blood cancer multiple myeloma, was discovered.
Mr. Lubner serves on the Board of Directors of Dyne Therapeutics, Therapeutics Acquisition Corp. (Nasdaq: TXAC), Gemini Therapeutics and Ichnos Sciences.
“Having just completed a $110 million Series B financing, Vor is well placed to build out its scientific platform and begin clinical trials in 2021,” said David Lubner. “Vor’s approach has the potential to radically change outcomes in patients suffering from acute myeloid leukemia and other blood cancers, and I look forward to contributing towards Vor’s success.”
A Certified Public Accountant, Mr. Lubner received his BS in business administration from Northeastern University and an MS in taxation from Bentley University.
About Vor Biopharma
Vor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell therapies. By removing biologically redundant proteins from eHSCs, these cells become inherently invulnerable to complementary targeted therapies while tumor cells are left susceptible, thereby unleashing the potential of targeted therapies to benefit cancer patients in need.
Vor’s platform could be used to potentially change the treatment paradigm of both hematopoietic stem cell transplants and targeted therapies, such as antibody-drug conjugates, bispecific antibodies and CAR-T cell treatments.
Vor is based in Cambridge, Mass. and has a broad intellectual property base, including in-licenses from Columbia University, where foundational work was conducted by inventor and Vor Scientific Board Chair Siddhartha Mukherjee, MD, DPhil.
For more information: https://www.vorbiopharma.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.